Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

NCT ID
NCT07831577
Registry status
Not yet recruiting
Study type
Interventional
Phase
Phase 2 / Phase 3
Sponsor
Genascence Corporation
Conditions
Knee Arthritis, Knee Arthritis Disease, Knee Arthritis Osteoarthritis, Knee Arthritis, Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis of the Knee, Osteoarthritic Knee Pain, Osteoarthritis (OA) of the Knee, Pain (Knee)

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Randomized, Double-blind, Placebo-controlled, Phase 2/3, Study to Evaluate the Efficacy and Safety of an Intraarticular Injection of GNSC-001 in Participants With Osteoarthritis of the Knee

Enrollment: 240 participants (Estimated).

What is being studied

  • Drug: Gene Therapy GNSC-001
  • Drug: Placebo

Who may be eligible

Ages
40 Years to 80 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Key Inclusion Criteria: * OA in the target knee confirmed by radiograph and with a Kellgren-Lawrence (KL) score of 2 or 3 * OA symptoms affecting the target knee present for at least 6 months * NRS pain score 5-9 (0-10 scale) in the target knee within the 24 hours prior to the time of consent * Synovitis and/or effusion detectable on imaging * Willing to stop use of any medication taken for knee OA pain for the duration of the study, including but not limited to nonsteroidal anti-inflammatory drugs (NSAIDs) * Able to provide written informed consent and comply with the requirements of the study Key Exclusion Criteria: * Body mass index (BMI) \> 38 kg/m2 * NRS pain score in other (non-target) knee ≥ 4 * Large effusion, substantial malalignment, structural compromise, prior partial or total joint replacement of target knee * Surgery on the target knee within the 6 months prior to screening or the anticipated need for treatment of either knee prior to the Month 12 Visit. * Current or history of inflammatory conditions (e.g., gout or rheumatoid arthritis), other joint disorders, septic arthritis, nerve damage or injury, chronic pain not associated with knee OA (e.g., fibromyalgia, hip OA), or otherwise immunocompromised * Active infection * Uncontrolled diabetes mellitus, glycosylated hemoglobin (HbA1c) \>7.0% at screening * Initiation of GLP-1RA, or similar medication, within the last 12 months, or discontinued within last 6 months prior to Screening * Use of opioid medications (including tramadol or tapentadol) or medical/recreational cannabinoids (oral/inhaled) for \> 5 days within the last 30 days * Use of medications for the treatment of chronic pain, immunosuppressant medications, or intra-articular injections into the target knee within 90 days of Day 1 * Current use of anticoagulant therapy * Received live vaccine within 6 weeks of Day 1 * Participation in another interventional clinical study with experimental therapy within 90 days prior to screening * Relies on a walking aids (e.g., cane, crutch, walker, wheelchair) or a personal assistant * Pregnant, breastfeeding, or intending to become pregnant during the study

Study locations

No study locations are listed in the registry data.

Study details

Start date
July 1, 2027
Primary completion date
October 1, 2029
Completion date
October 1, 2030
First posted
September 21, 2026

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07831577
Registry last updated
September 21, 2026
QualifiedStudies registry data refreshed
October 5, 2026
QualifiedStudies record fetched
October 5, 2026

View NCT07831577 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Knee Pain studies | Clinical trial FAQ